Advertisement

Topics

Prostate Oncology Specialists, Inc. Company Profile

03:07 EDT 23rd March 2019 | BioPortfolio

According to the American Cancer Society, prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than two million men in the United States have prostate cancer, with an estimated 217,730 new cases and approximately 32,050 men expected to die from the disease in 2010.


News Articles [1579 Associated News Articles listed on BioPortfolio]

Time to biochemical failure could be used as surrogate endpoint in treatment: LA prostate cancer

(NRG Oncology) An analysis of the NRG Oncology clinical trial NRG-RTOG 9202 showed that the interval of time to biochemical failure (IBF), or the time it takes for previously treated cancer to return ...

GU/Prostate Cancer | Medscape

Review in-depth clinical information, latest medical news, and guidelines on prostate cancer and prostate cancer treatment including prostate cancer surgery. Learn about prostate cancer prognosis for ...

Inflammatory Bowel Disease Linked to Prostate Cancer

NewsMen with inflamed guts are four to five times at risk for prostate cancer.Contributed Author: 

Which Approach is Best for Biopsy Gleason Score 9–10 Prostate Cancer?

A recent study in JAMA Oncology compared survival for various multi-modality approaches for treating aggressive prostate cancer.

Prostate cancer researchers win $2m to explore carboplatin therapy

The US Department of Defence has awarded a coalition of researchers – made up of the Prostate Cancer Clinical Research Unit of the Spanish National Cancer Research Center (CNIO), the Prostate Cancer...

Hypofractionated RT should be considered new practice standard for men with low risk prostate cancer

(NRG Oncology) Results from the NRG Oncology clinical study NRG-RTOG 0415 determined that a hypofractionated radiotherapy schedule (H-RT), a treatment schedule that delivers a total dose of radiothera...

Clovis Oncology shares pop after prostate cancer drug Rubraca gets 'breakthrough therapy' designation

The review of Rubraca by the FDA for the treatment of BRCA ½ mutated metastatic castration-resistant prostate cancer will be expedited

Hypofractionated Radiation OK for Localized Prostate CA

MONDAY, Oct. 29, 2018 -- A new clinical guideline for early-stage prostate cancer supports the use of shortened courses of radiation therapy, according to an article published in Practical Radiation O...

PubMed Articles [2482 Associated PubMed Articles listed on BioPortfolio]

Consensus on management of castration-resistant prostate cancer on behalf of the Urological Tumours Working Group (URONCOR) of the Spanish Society of Radiation Oncology.

The knowledge in the field of castration-resistant prostate cancer (CRPC) is developing rapidly, with emerging new therapies and advances in imaging. Nonetheless, in multiple areas there is still a la...

Effect of Chemotherapy With Docetaxel With Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer: The Randomized Phase III NRG Oncology RTOG 0521 Trial.

Radiotherapy (RT) plus long-term androgen suppression (AS) are a standard treatment option for patients with high-risk localized prostate cancer. We hypothesized that docetaxel chemotherapy (CT) could...

Patient-Centered Preference Assessment to Improve Satisfaction With Care Among Patients With Localized Prostate Cancer: A Randomized Controlled Trial.

To study the effectiveness of the Patient Preferences for Prostate Cancer Care (PreProCare) intervention in improving the primary outcome of satisfaction with care and secondary outcomes of satisfacti...

Effect of Adding Docetaxel to Androgen-Deprivation Therapy in Patients With High-Risk Prostate Cancer With Rising Prostate-Specific Antigen Levels After Primary Local Therapy: A Randomized Clinical Trial.

Androgen-deprivation therapy (ADT) plus docetaxel is the standard of care in hormone-naive metastatic prostate cancer but is of uncertain benefit in a nonmetastatic, high-risk prostate cancer setting.

Prevalence of Germline Variants in Prostate Cancer and Implications for Current Genetic Testing Guidelines.

Prostate cancer is the third leading cause of cancer-related death in men in the United States. Although serious, most of these diagnoses are not terminal. Inherited risk for prostate cancer is associ...

Clinical Trials [3339 Associated Clinical Trials listed on BioPortfolio]

Mind-Body Health in Uro-Oncology: Research Study

In this study, the researchers will examine the effects of post-mindfulness intervention email and text messages to promote maintenance of intervention effects over time in a uro-oncology ...

Stereotactic Prostate Adaptive Radiotherapy Utilising Kilovoltage Intrafraction Monitoring

The SPARK trial is testing the use of Kilovoltage Intrafraction Monitoring in prostate cancer patients being treated with Stereotactic Prostate Adaptive Radiotherapy. The researchers expe...

Evaluation and Management for Prostate Oncology, Wellness, and Risk (EMPOWeR)

The EMPOWeR study is proposed as a cohort study with longitudinal follow-up to determine rates of genetic mutations among men with or at-risk for prostate cancer to address the various fac...

Collection of Blood From Patients With Prostate Cancer

Background: - It is not fully understood why prostate cancer in some men becomes androgen-independent (no longer responds to anti-androgen medication), but genetics likely plays a...

PALLiON - PALLiative Care In ONcology

A major concern in today's oncology is the complexity of treatment that increases costs. A main contributor is the increasing use of chemo- and radiotherapy during end of life (EoL: the la...

Companies [1390 Associated Companies listed on BioPortfolio]

Prostate Oncology Specialists,Inc.

Prostate Oncology Specialists is a medical group exclusively devoted to caring for men with prostate cancer. We have vast experience diagnosing and treating prostate cancer because 100% of our time is...

Prostate Oncology Specialists, Inc.

According to the American Cancer Society, prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than two million men in the United St...

Texas Oncology

Texas Oncology delivers high-quality cancer care with leading-edge technology and advanced treatment and therapy options available to help patients achieve “More breakthrough...

Minomic International Ltd

Minomic International Ltd is an Australian immuno-oncology company specialising in therapeutics and diagnostics for prostate cancer and other cancers. Minomic has developed the in...

Prostate Cancer Foundation

The Prostate Cancer Foundation (PCF) is the world’s largest philanthropic source of support for accelerating the world’s most promising research for discovering better t...

More Information about "Prostate Oncology Specialists, Inc." on BioPortfolio

We have published hundreds of Prostate Oncology Specialists, Inc. news stories on BioPortfolio along with dozens of Prostate Oncology Specialists, Inc. Clinical Trials and PubMed Articles about Prostate Oncology Specialists, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Prostate Oncology Specialists, Inc. Companies in our database. You can also find out about relevant Prostate Oncology Specialists, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Skin cancers
There are three main types of skin cancer: basal cell carcinoma, squamous cell carcinoma and malignant melanoma. Basal cell carcinoma Basal cell carcinoma, or BCC, is a cancer of the basal cells at the bottom of the epidermis. It’s very common ...


Corporate Database Quicklinks



Searches Linking to this Company Record